Franco Folli
Overview
Explore the profile of Franco Folli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
3677
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fava M, Pani L, De Martin S, Cutler A, Gorodetzky C, Vocci F, et al.
J Clin Psychiatry
. 2025 Feb;
86(1).
PMID: 39999772
Esmethadone is a novel -methyl-D-aspartate receptor (NMDAR) uncompetitive antagonist in development as adjunctive treatment for major depressive disorder (MDD). This 12-month, open-label study evaluated the safety and efficacy of esmethadone...
2.
Berra C, Manfrini R, Bifari F, Cipponeri E, Ghelardi R, Centofanti L, et al.
Pharmacol Res
. 2025 Feb;
213:107640.
PMID: 39900210
No abstract available.
3.
Comai S, De Martin S, Mattarei A, Guidetti C, Pappagallo M, Folli F, et al.
Pharmaceuticals (Basel)
. 2025 Jan;
17(12.
PMID: 39770460
Uncompetitive NMDAR (N-methyl-D-aspartate receptor) antagonists restore impaired neural plasticity, reverse depressive-like behavior in animal models, and relieve major depressive disorder (MDD) in humans. This review integrates recent findings from in...
4.
Berra C, Manfrini R, Bifari F, Cipponeri E, Ghelardi R, Centofanti L, et al.
Pharmacol Res
. 2024 Nov;
210:107517.
PMID: 39613122
We evaluated the effects on glycemic control and body weight of a GLP1-RA in obese type 2 diabetic patients treated with SGLT2-inhibitors and other hypoglycemic agents and/or insulin, in a...
5.
Pontiroli A, Centofanti L, Zakaria A, Cerutti S, Cas M, Paroni R, et al.
Diabetes Metab Syndr
. 2024 Nov;
18(10):103146.
PMID: 39515184
Background: The Triglyceride-Glucose Index (TYG) has been proposed as a prognostic index for mortality in the general population, in T2DM, and in patients with cardiovascular diseases. However, data on the...
6.
Bignotto M, Bianco E, Centofanti L, Russo A, Cas M, Zermiani P, et al.
Am J Physiol Endocrinol Metab
. 2024 Aug;
327(4):E498-E511.
PMID: 39196799
The CA.ME.LI.A (CArdiovascular risks, MEtabolic syndrome, LIver and Autoimmune disease) epidemiological study was conducted in Abbiategrasso (Milan, Italy) to identify risk factors for metabolic and cardiovascular disease in an apparently...
7.
Ferri N, De Martin S, Stuart J, Traversa S, Mattarei A, Comai S, et al.
Drugs R D
. 2024 Aug;
24(2):341-352.
PMID: 39095578
Background And Objectives: Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is a low potency N-methyl--aspartate (NMDA) receptor channel blocker that showed a rapid and sustained adjunctive antidepressant effects in patients with...
8.
Fava M, Stahl S, Pani L, De Martin S, Cutler A, Maletic V, et al.
J Clin Psychiatry
. 2024 Jun;
85(3).
PMID: 38917366
To test esmethadone (REL-1017) as adjunctive treatment in patients with major depressive disorder (MDD) and inadequate response to standard antidepressants. In this phase 3, double-blind, placebo-controlled trial, outpatients with MDD...
9.
Ben Nasr M, Usuelli V, Dellepiane S, Seelam A, Fiorentino T, DAddio F, et al.
Cell Metab
. 2024 Jun;
36(6):1302-1319.e12.
PMID: 38838642
Glucagon-like peptide-1 receptor (GLP-1R) is a key regulator of glucose metabolism known to be expressed by pancreatic β cells. We herein investigated the role of GLP-1R on T lymphocytes during...
10.
Guidetti C, De Martin S, Serra G, Apicella M, Pani L, Pappagallo M, et al.
J Clin Psychiatry
. 2024 May;
85(2).
PMID: 38767937
The relationship between the duration of major depressive disorder (MDD) and therapeutic response to standard antidepressant treatment (SAT) is unknown. -methyl-D-aspartate receptor uncompetitive antagonists are emerging drugs for MDD. We...